Industry Spotlight: BioROSA
BioROSA is developing a highly accurate blood test that will detect ASD in children as young as 18 months. According to the CDC, Autism Spectrum Disorder (ASD) is estimated to affect 1 in 54 children in the United States. Currently, ASD is diagnosed on the basis of surface symptoms and treated behaviorally. There is at present no blood test that can be ordered to assess ASD risk.
Clinically validated biomarkers that enable earlier identification, diagnosis and access to treatment have the potential to greatly improve outcomes in a child with autism. Certain biomarkers will also enable better characterization of patients through objective and quantifiable means, leading to more individualized therapies for patients.
Through a combination of machine learning and proprietary laboratory science, BioROSA has produced a highly accurate and robust diagnostic solution for ASD. The test uses a small amount of blood taken from a standard blood draw and measures a set of blood biomarkers that are predictors of ASD. Computer algorithms are then applied to analyze the data and provide a risk score for the condition. To date, the BioROSA test can discriminate whether a blood sample comes from a child with ASD or not with over 95% accuracy.